Last reviewed · How we verify
adeno-associated virus vector AAV- CNGA3
adeno-associated virus vector AAV- CNGA3 is a Biologic drug developed by MeiraGTx UK II Ltd. It is currently in Phase 1 development.
At a glance
| Generic name | adeno-associated virus vector AAV- CNGA3 |
|---|---|
| Sponsor | MeiraGTx UK II Ltd |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Conjunctival haemorrhage
- Visual acuity reduced
- Vomiting
- Conjunctival hyperaemia
- Lenticular opacities
- Ocular discomfort
- Eye pain
- Photophobia
- Intraocular pressure increased
- Intraocular pressure decreased
- Diarrhoea
- Nausea
Key clinical trials
- Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNGA3
- Gene Therapy for Achromatopsia (CNGA3) (PHASE1, PHASE2)
- Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia (A Clarity Clinical Trial) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- adeno-associated virus vector AAV- CNGA3 CI brief — competitive landscape report
- adeno-associated virus vector AAV- CNGA3 updates RSS · CI watch RSS
- MeiraGTx UK II Ltd portfolio CI
Frequently asked questions about adeno-associated virus vector AAV- CNGA3
What is adeno-associated virus vector AAV- CNGA3?
adeno-associated virus vector AAV- CNGA3 is a Biologic drug developed by MeiraGTx UK II Ltd.
Who makes adeno-associated virus vector AAV- CNGA3?
adeno-associated virus vector AAV- CNGA3 is developed by MeiraGTx UK II Ltd (see full MeiraGTx UK II Ltd pipeline at /company/meiragtx-uk-ii-ltd).
What development phase is adeno-associated virus vector AAV- CNGA3 in?
adeno-associated virus vector AAV- CNGA3 is in Phase 1.
What are the side effects of adeno-associated virus vector AAV- CNGA3?
Common side effects of adeno-associated virus vector AAV- CNGA3 include Conjunctival haemorrhage, Visual acuity reduced, Vomiting, Conjunctival hyperaemia, Lenticular opacities, Ocular discomfort.